News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
GlaxoSmithKline Says Cervical Cancer Vaccine Works for Longer
May 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, May 14 (Reuters) - GlaxoSmithKline said on Wednesday new data showed its Cervarix vaccine generated sustained, high levels of neutralising antibodies against the two most common cervical cancer-causing virus types for 6.4 years.
Twitter
LinkedIn
Facebook
Email
Print
Europe
GSK
MORE ON THIS TOPIC
Insights
Can Europe turn world-class science into world-class scale?
April 16, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Drug pricing
Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is Chilling
April 2, 2026
·
3 min read
·
Annalee Armstrong
Drug pricing
Trump’s MFN Pricing Expected To Delay More European Drug Launches
April 1, 2026
·
3 min read
·
Nick Paul Taylor
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
·
1 min read
·
Nick Paul Taylor
